Common Myths and Misconceptions That Sidetrack Parkinson Disease Treatment, to the Detriment of Patients

Ahlskog, J. Eric

doi:10.1016/j.mayocp.2020.02.006

Cited by 4 publications

(8 citation statements)

References 59 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential neurotoxicity of carbidopa/levodopa has been suggested [62]. However, Ahlskog recently reviewed and refuted the evidence that carbidopa/levodopa is neurotoxic [63].…”

Section: Therapy Options For Treating Motor Symptoms Of Pdmentioning

confidence: 99%

Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease

Church

2021

Biomolecules

131

View full text Add to dashboard Cite

Parkinson’s disease (PD) usually presents in older adults and typically has both motor and non-motor dysfunctions. PD is a progressive neurodegenerative disorder resulting from dopaminergic neuronal cell loss in the mid-brain substantia nigra pars compacta region. Outlined here is an integrative medicine and health strategy that highlights five treatment options for people with Parkinson’s (PwP): rehabilitate, therapy, restorative, maintenance, and surgery. Rehabilitating begins following the diagnosis and throughout any additional treatment processes, especially vis-à-vis consulting with physical, occupational, and/or speech pathology therapist(s). Therapy uses daily administration of either the dopamine precursor levodopa (with carbidopa) or a dopamine agonist, compounds that preserve residual dopamine, and other specific motor/non-motor-related compounds. Restorative uses strenuous aerobic exercise programs that can be neuroprotective. Maintenance uses complementary and alternative medicine substances that potentially support and protect the brain microenvironment. Finally, surgery, including deep brain stimulation, is pursued when PwP fail to respond positively to other treatment options. There is currently no cure for PD. In conclusion, the best strategy for treating PD is to hope to slow disorder progression and strive to achieve stability with neuroprotection. The ultimate goal of any management program is to improve the quality-of-life for a person with Parkinson’s disease.

show abstract

“…The potential neurotoxicity of carbidopa/levodopa has been suggested [62]. However, Ahlskog recently reviewed and refuted the evidence that carbidopa/levodopa is neurotoxic [63].…”

Section: Therapy Options For Treating Motor Symptoms Of Pdmentioning

confidence: 99%

Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease

Church

2021

Biomolecules

131

View full text Add to dashboard Cite

show abstract

“…The association of parental psychopathology in neurometabolic (e.g., Wilson's disease) and neuroimmunological diseases (including demyelinating diseases of CNS) are yet to be established. [107][108][109][110][111][112][113][114] However, our lifetime observations have revealed various psychopathologies among parents/caregivers that are not merely explained by depression and anxiety related to the sufferings of their children/closer ones from severe neurological ailments. This might probably be arising from the truncated or partial effect(s) of the same genetic mutation(s) their children are harboring, resulting in the expression of underestimated behavioral counterpart of the same disease conundrum.…”

Section: Parental Psychopathologymentioning

confidence: 99%

“…This might probably be arising from the truncated or partial effect(s) of the same genetic mutation(s) their children are harboring, resulting in the expression of underestimated behavioral counterpart of the same disease conundrum. [107][108][109][110][111][112][113][114] The same applies to various neurodegenerative diseases.…”

Section: Parental Psychopathologymentioning

confidence: 99%

“…This only firmly postulates that neurodegenerative diseases have their pathogenetic clue, potentially hidden much upstream, and can have either isolated neurological or psychiatric manifestations or expression of disease through the plane of neuropsychiatric convergence. [107][108][109][110][111][112][113][114] The strong association between neuroticism and the development of Alzheimer's disease in later life also holds the notion of neuropsychiatric convergence firmly. It can be extrapolated to any disease entity started in either way and finally merged into a neuropsychiatric continuum.…”

Section: Parental Psychopathologymentioning

confidence: 99%

“…These issues get further complicated by poverty and unemployment and evolve around consanguinity, the harbinger of cumulative neuropsychiatric disease burden within the family. [107][108][109][110][111][112][113][114]…”

Section: Parental Psychopathologymentioning

confidence: 99%

See 2 more Smart Citations

Psychosocial Basis of Human Sufferings and Poverty in Patients with Neurological and Psychiatric Disorders

Dubey,

Ghosh,

Dubey

et al. 2023

MRAJ

View full text Add to dashboard Cite

Neurological disorders and psychiatric ailments often lead to cognitive disabilities and low attainment of education, pivoting misconceptions, myths, and misbeliefs. Poverty and low educational attainment are intriguingly associated with poor awareness and perception of these diseases that add to the suffering. Poverty goes parallel with a low level of education and is intricately associated with neuropsychiatric ailments, which have the potential to spread transgenerationally. Robust education policies, proper government rules and regulations against the spread of disease-related myths and misconceptions, uplifting medical education in its true sense, voices against consanguinity, and programs to raise scientific perception about diseases can help to throw light at the end of this dark tunnel. In this article, the authors intend to 1) decipher the potential psychosocial basis of human suffering and poverty in patients with neurological and psychiatric disorders, and 2) discuss the apropos way-outs that would potentially mitigate suffering, and alleviate the economic burden and cognitive disabilities of families with neuropsychiatric diseases.

show abstract

Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty

et al. 2023

View full text Add to dashboard Cite

Device-aided therapies (DAT), which include deep brain stimulation and pump-based continuous dopaminergic stimulation with either levodopa or apomorphine, are among the major advances in the clinical management of Parkinson’s disease (PD). Although DAT are being increasingly offered earlier in the disease course, their classical indication remains advanced PD. Theoretically, every patient should be offered transition to DAT when faced with refractory motor and nonmotor fluctuations and functional decline. Worldwide clinical reality is far from these ideal, and, therefore, question the “real-world” equal opportunity of access to DAT for PD patients with advanced PD—even within a single health care system. Differences in access to care, referral pattern (timing and frequency), as well as physician biases (unconscious/implicit or conscious/explicit bias), and patients’ preferences or health-seeking behaviour are to be considered. Compared to DBS, little information is available concerning infusion therapies, as well as neurologists’ and patients’ attitudes towards them. This viewpoint aims to be thought-provoking and to assist clinicians in moving through the process of DAT selection, by including in their decision algorithm their own biases, patient perspective, ethical concerns as well as the current unknowns surrounding PD prognosis and DAT-related long-term side effects for a given patient.

show abstract

Common Myths and Misconceptions That Sidetrack Parkinson Disease Treatment, to the Detriment of Patients

Cited by 4 publications

References 59 publications

Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease

Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease

Psychosocial Basis of Human Sufferings and Poverty in Patients with Neurological and Psychiatric Disorders

Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty

Contact Info

Product

Resources

About